ATC code L Antineoplastic and immunomodulating agents is a section of the Anatomical Therapeutic Chemical Classification System, a system of alphanumeric codes developed by the WHO for the classification of drugs and other medical products.[1]
Codes for
veterinary use (
ATCvet codes) can be created by placing the letter Q in front of the human ATC code:
QL...
[2] National issues of the ATC classification may include additional codes not present in this list, which follows the WHO version.
References
Cite error: Invalid <references> tag;
parameter "group" is allowed only.
Use
<references />, or
<references group="..." />
|
|---|
| CI monoclonal antibodies ("-mab") | |
|---|
| Tyrosine kinase inhibitors ("-nib") | | ErbB: HER1/EGFR ( Erlotinib, Gefitinib, Vandetanib) · HER1/EGFR and HER2/neu ( BIBW 2992, Lapatinib, Neratinib)
RTK class III: C-kit and PDGFR (Axitinib, Pazopanib, Sunitinib, Sorafenib, Toceranib) · FLT3 (Lestaurtinib)
VEGFR ( Axitinib, Cediranib, Pazopanib, Regorafenib, Semaxanib, Sorafenib, Sunitinib, Toceranib, Vandetanib) |
|---|
| |
|---|
|
|---|
| Other | |
|---|
|
|
|---|
| Endogenous | | |
|---|
Other protein/peptide | |
|---|
Other | |
|---|
|
|---|
| Exogenous | |
|---|
|
|
|---|
Intracellular
(initiation) | |
|---|
Intracellular
(reception) | |
|---|
| Extracellular | | | Serum target
(noncellular) | |
|---|
Cellular target | CD3 ( Muromonab-CD3, Otelixizumab, Teplizumab, Visilizumab) · CD4 ( Clenoliximab, Keliximab, Zanolimumab) · CD11a ( Efalizumab) · CD18 ( Erlizumab) · CD20 ( Afutuzumab, Ocrelizumab, Pascolizumab) · CD23 ( Lumiliximab) · CD40 ( Teneliximab, Toralizumab) · CD62L/L-selectin ( Aselizumab) · CD80 ( Galiximab) · CD147/Basigin ( Gavilimomab) · CD154 ( Ruplizumab)
BLyS (Belimumab) · CTLA-4 (Ipilimumab, Tremelimumab) · CAT (Bertilimumab, Lerdelimumab, Metelimumab) · Integrin (Natalizumab) · Interleukin-6 receptor (Tocilizumab) · LFA-1 (Odulimomab)
IL-2 receptor/CD25 (Basiliximab, Daclizumab, Inolimomab)
T-lymphocyte ( Zolimomab aritox) |
|---|
Unsorted | Atorolimumab, Cedelizumab, Dorlixizumab, Fontolizumab, Gantenerumab, Gomiliximab, Maslimomab, Morolimumab, Pexelizumab, Reslizumab, Rovelizumab, Siplizumab, Talizumab, Telimomab aritox, Vapaliximab, Vepalimomab |
|---|
|
|---|
| |
|---|
|
|---|
| |
|---|
|
|---|
|
- ↑ "ATC Index". WHO Collaborating Centre for Drug Statistics Methodology.
- ↑ "ATCvet Index". WHO Collaborating Centre for Drug Statistics Methodology.
